Cargando…

P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)

Detalles Bibliográficos
Autores principales: Nastoupil, L. J., O’Brien, S., Holmes, H. E., Dsouza, L., Hart, D., Matsuda, E., Satterfield-Ledbetter, T., Skoble, J., Garner, E., Bryan, M., Kanner, S., Li, E., Thomas, C. T., Essell, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431188/
http://dx.doi.org/10.1097/01.HS9.0000848676.15840.df
_version_ 1784779983799975936
author Nastoupil, L. J.
O’Brien, S.
Holmes, H. E.
Dsouza, L.
Hart, D.
Matsuda, E.
Satterfield-Ledbetter, T.
Skoble, J.
Garner, E.
Bryan, M.
Kanner, S.
Li, E.
Thomas, C. T.
Essell, J.
author_facet Nastoupil, L. J.
O’Brien, S.
Holmes, H. E.
Dsouza, L.
Hart, D.
Matsuda, E.
Satterfield-Ledbetter, T.
Skoble, J.
Garner, E.
Bryan, M.
Kanner, S.
Li, E.
Thomas, C. T.
Essell, J.
author_sort Nastoupil, L. J.
collection PubMed
description
format Online
Article
Text
id pubmed-9431188
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94311882022-08-31 P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY) Nastoupil, L. J. O’Brien, S. Holmes, H. E. Dsouza, L. Hart, D. Matsuda, E. Satterfield-Ledbetter, T. Skoble, J. Garner, E. Bryan, M. Kanner, S. Li, E. Thomas, C. T. Essell, J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431188/ http://dx.doi.org/10.1097/01.HS9.0000848676.15840.df Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Nastoupil, L. J.
O’Brien, S.
Holmes, H. E.
Dsouza, L.
Hart, D.
Matsuda, E.
Satterfield-Ledbetter, T.
Skoble, J.
Garner, E.
Bryan, M.
Kanner, S.
Li, E.
Thomas, C. T.
Essell, J.
P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)
title P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)
title_full P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)
title_fullStr P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)
title_full_unstemmed P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)
title_short P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)
title_sort p1455: first-in-human trial of cb-010, a crispr-edited allogeneic anti-cd19 car -t cell therapy with a pd-1 knock out, in patients with relapsed or refractory b cell non-hodgkin lymphoma (antler study)
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431188/
http://dx.doi.org/10.1097/01.HS9.0000848676.15840.df
work_keys_str_mv AT nastoupillj p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT obriens p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT holmeshe p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT dsouzal p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT hartd p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT matsudae p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT satterfieldledbettert p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT skoblej p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT garnere p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT bryanm p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT kanners p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT lie p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT thomasct p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy
AT essellj p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy